The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine - 27/05/22
Abstract |
Clinically, cancer drug therapy is still dominated by chemotherapy drugs. Although the emergence of targeted drugs has greatly improved the survival rate of patients with advanced cancer, drug resistance has always been a difficult problem in clinical cancer treatment. At the current level of medicine, most drugs cannot escape the fate of drug resistance. With the emergence and development of gene detection, liquid biopsy ctDNA technology, and single-cell sequencing technology, the molecular mechanism of tumor drug resistance has gradually emerged. Drugs can also be updated in response to drug resistance mechanisms and bring higher survival benefits. The use of new drugs often leads to new mechanisms of resistance. In this review, the multi-molecular mechanisms of drug resistance are introduced, and the overcoming of drug resistance is discussed from the perspective of the tumor microenvironment.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Immunotherapy mayreplace chemotherapy in the future, but mechanisms of potential drug resistance are unknown. |
• | TME and ncRNA have significant effects on tumor resistance, which will be one of the key research directions in the future. |
• | CSC is the main cause of tumor drug resistance. |
• | Targeted drugs are difficult to overcome drug resistance and often cause drug resistance due to mutations in the targets. |
• | The metabolism-related resistance can be overcome by targeting tumor metabolic pathways. |
Abbreviations : 5-FU, ASCL1, ALL, ACT, ALDH1A1, ALK, AR, ASO, Aurora A, AURKA, BCR, BDNF, BTK, CAF, CARs, CAR-T, CDK1, CLL, CML, circRNA, CRC, CSCs, CTLA-4, DOX, ER+, ERK, ESR1, FGFR1, GSCs, HDF, HGF, ICIs, IFN, IGF1R, IL-33, ITH, lncRNA, MCL, MDR, MET, miRNAs, mtDNA, ncRNA, NK, NGF, NT-3, NSCLC, OCT1, PANDAR, P-gp, PI3Ks, PKM2, PLK1, PSTI, PTBP1, RNAi, RTKs, SASP, SCLC, SLL, SPINK1, TATI, TAM, TGF-B, TIM-3, TKIs, TME, TRK, tSCs, TUG1, UHRF1, UTR
Keywords : Drug resistance, Molecular mechanisms, Targeted drugs, Tumor immune escape, Tumor microenvironment
Plan
Vol 150
Article 113064- juin 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?